- NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
- N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
- ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
- ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
- ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
More ▼
Key statistics
On Thursday, Immunitybio Inc (IBRX:NSQ) closed at 5.37, -22.51% below its 52-week high of 6.93, set on May 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.41 |
---|---|
High | 5.82 |
Low | 5.35 |
Bid | 5.40 |
Offer | 5.42 |
Previous close | 5.46 |
Average volume | 5.17m |
---|---|
Shares outstanding | 673.95m |
Free float | 137.03m |
P/E (TTM) | -- |
Market cap | 3.68bn USD |
EPS (TTM) | -1.13 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼